Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
AstraZeneca
Toray Industries, Inc
Lisata Therapeutics, Inc.
Universitätsklinikum Hamburg-Eppendorf